Literature DB >> 8532427

Respiratory virus infections during anticancer treatment in children.

M Arola1, O Ruuskanen, T Ziegler, T T Salmi.   

Abstract

To evaluate the occurrence and clinical significance of respiratory virus infections in children during anticancer treatment, we studied 75 consecutive episodes of febrile infection in 32 children during 17 months. Viral antigen detection for 7 respiratory viruses, viral culture for rhinoviruses and enzyme immunoassay serology were used. Evidence for respiratory virus infection was found in 28 (37%) cases. Rhinovirus was the most common virus detected in 13 (17%) episodes. The other etiologic agents were respiratory syncytial virus (6 episodes), parainfluenza virus type 3 (5 episodes), adenovirus (4 episodes), influenza A virus (3 episodes), and influenza B virus (1 episode). Respiratory virus infections were diagnosed as often in leukopenic as in non-leukopenic patients (37% vs. 38%). In 4 cases bacteremic infection was diagnosed. We found no difference in serum C-reactive protein values when episodes positive for respiratory viruses were compared with virus-negative episodes. Our observations show that respiratory virus infections are common in febrile children receiving anticancer treatment. Diagnostic tests for respiratory viruses should be used more often in evaluation of fever in these patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8532427     DOI: 10.1097/00006454-199508000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  20 in total

1.  Clinical and demographic characteristics of seasonal influenza in pediatric patients with cancer.

Authors:  Silvana B Carr; Elisabeth E Adderson; Hana Hakim; Xiaoping Xiong; Xiaowei Yan; Miguela Caniza
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

2.  Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.

Authors:  Christian Jogler; Dennis Hoffmann; Dirk Theegarten; Thomas Grunwald; Klaus Uberla; Oliver Wildner
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Viral findings during febrile episodes after cytotoxic chemotherapy in patients with hematological malignancies.

Authors:  E M Rintala; J Nikoskelainen; T Ziegler; R Jussila
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

4.  Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma.

Authors:  Noa Lavi; Irit Avivi; Zipora Kra-Oz; Ilana Oren; Emilia Hardak
Journal:  Support Care Cancer       Date:  2018-02-09       Impact factor: 3.603

5.  Simultaneous detection and identification of human parainfluenza viruses 1, 2, and 3 from clinical samples by multiplex PCR.

Authors:  J E Echevarría; D D Erdman; E M Swierkosz; B P Holloway; L J Anderson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 6.  Influenza vaccination in children being treated with chemotherapy for cancer.

Authors:  Ginette M Goossen; Leontien C M Kremer; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01

7.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

8.  Parainfluenza virus infections in children with hematologic malignancies.

Authors:  Ashok Srinivasan; Chong Wang; Jie Yang; Hiroto Inaba; Jerry L Shenep; Wing H Leung; Randall T Hayden
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

Review 9.  Protecting pediatric oncology patients from influenza.

Authors:  Leslie S Kersun; Anne F Reilly; Susan E Coffin; Kathleen E Sullivan
Journal:  Oncologist       Date:  2013-01-31

Review 10.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.